BeiGene, Ltd. announced the opening of its U.S. facility in Hopewell, N.J., at the Princeton West Innovation Campus, which houses biologics manufacturing capabilities and a clinical research and development center that further bolster the Company's differentiated model as an oncology innovator. BeiGene has more than 30 molecules at clinical or commercial stage, and the 42-acre facility provides flexibility to scale production of its innovative medicines and in the future to meet the needs of patients with cancer. BeiGene's $800 million investment is the culmination of a three-year project to expand the Company's integrated manufacturing and research and development footprint in the U.S. BeiGene will create hundreds of skilled high-tech jobs at the site by the end of 2025.

New Jersey is a global leader in biopharmaceutical manufacturing and R&D with nine of the top 10 R&D companies in the world having a presence in the state. New Jersey boasts one of the country's leading biopharmaceutical manufacturing workforces, and its infrastructure and connectivity ensure access to major markets around the world. The site features approximately 400,000 square feet of dedicated commercial-stage biologic pharmaceutical manufacturing capacity with space to expand over time, allowing flexibility as BeiGene?s pipeline continues to mature.

The facility adds to BeiGene?s late-stage research and clinical development capabilities, which have enabled the Company?s fast rise to global oncology leadership. BeiGene has built one of the industry?s deepest and most compelling oncology pipelines, addressing 80 percent of the world?s cancers with innovative modalities such as targeted degraders and antibody drug conjugates (ADCs), in addition to monoclonal antibodies and traditional small molecules. The new facility builds on BeiGene?s existing capabilities, enabling the Company to produce at scale, thereby reducing costs, ensuring supply chain resiliency, avoiding global disruptions, protecting capacity and rapidly adapting to the latest innovative modalities.

BeiGene recognizes that human health and the health of the planet are intrinsically linked, and the Company is committed to reducing our environmental impact. For this reason, the Company has invested in sustainability measures both in the buildings and surrounding 42 acres, including a heating and cooling system that uses recycled wastewater from the onsite wastewater treatment plant for the cooling towers. The site also is solar-ready in line with our longer-term sustainability plan.